Prophylactic and Therapeutic Modulation of Innate and Adaptive Immunity Against Mucosal Infection of Herpes Simplex Virus.
- Author:
Erdenebileg UYANGAA
1
;
Ajit Mahadev PATIL
;
Seong Kug EO
Author Information
- Publication Type:Review
- Keywords: Herpes simplex virus; Mucosal infection; Innate immunity; Adaptive immunity; Toll-like receptors; Type I IFN receptors
- MeSH: Adaptive Immunity*; Dendritic Cells; Herpesvirus 1, Human; Humans; Immunity, Humoral; Immunity, Innate; Interferon Type I; Killer Cells, Natural; Mucous Membrane; Simplexvirus*; Social Control, Formal; T-Lymphocytes; Toll-Like Receptors; Ulcer; Viral Load
- From:Immune Network 2014;14(4):187-200
- CountryRepublic of Korea
- Language:English
- Abstract: Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are the most common cause of genital ulceration in humans worldwide. Typically, HSV-1 and 2 infections via mucosal route result in a lifelong latent infection after peripheral replication in mucosal tissues, thereby providing potential transmission to neighbor hosts in response to reactivation. To break the transmission cycle, immunoprophylactics and therapeutic strategies must be focused on prevention of infection or reduction of infectivity at mucosal sites. Currently, our understanding of the immune responses against mucosal infection of HSV remains intricate and involves a balance between innate signaling pathways and the adaptive immune responses. Numerous studies have demonstrated that HSV mucosal infection induces type I interferons (IFN) via recognition of Toll-like receptors (TLRs) and activates multiple immune cell populations, including NK cells, conventional dendritic cells (DCs), and plasmacytoid DCs. This innate immune response is required not only for the early control of viral replication at mucosal sites, but also for establishing adaptive immune responses against HSV antigens. Although the contribution of humoral immune response is controversial, CD4+ Th1 T cells producing IFN-gamma are believed to play an important role in eradicating virus from the hosts. In addition, the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral burden at mucosal sites have accumulated. This review focuses on attempts to modulate innate and adaptive immunity against HSV mucosal infection for the development of prophylactic and therapeutic strategies. Notably, cells involved in innate immune regulations appear to shape adaptive immune responses. Thus, we summarized the current evidence of various immune mediators in response to mucosal HSV infection, focusing on the importance of innate immune responses.
